Analytical Data
-
Gene name
CXCL6
- Application
-
Alternative Names
CXCL6；GCP2；SCYB6；C-X-C motif chemokine 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P80162
-
Expression Region
43-114aa
-
AA Sequence
VLTELRCTCL RVTLRVNPKT IGKLQVFPAG PQCSKVEVVA SLKNGKQVCL DPEAPFLKKV IQKILDSGNK KN
-
Molecular Weight
7.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL6, also known as CXC chemokine ligand 6 or Gro-α, is a member of the CXC chemokine family that plays a crucial role in the immune response and inflammation. It is primarily produced by various cell types, including macrophages, fibroblasts, and endothelial cells, in response to pro-inflammatory stimuli. CXCL6 exhibits potent chemotactic properties, attracting neutrophils and other immune cells to sites of tissue injury or infection, thus participating in host defense mechanisms. Research has shown that CXCL6 is involved in various pathological conditions, including cancer, autoimmune diseases, and chronic inflammatory disorders. Its expression levels are often elevated in tumors, where it contributes to tumor progression, metastasis, and the creation of an immunosuppressive microenvironment. To further understand its biologic functions and therapeutic potential, the development of recombinant CXCL6 protein for in vitro and in vivo studies has gained significant interest. This recombinant protein can be used to explore the mechanisms by which CXCL6 influences immune cell behavior, its role in disease processes, and potential applications in targeted therapies. Understanding CXCL6's interactions and signaling pathways could pave the way for novel therapeutic strategies aimed at modulating immune responses and improving outcomes in diseases characterized by dysregulated inflammation or immune evasion.
